202 related articles for article (PubMed ID: 20965941)
1. Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1.
Tsukamoto T; Shinohara N; Tsuchiya N; Hamamoto Y; Maruoka M; Fujimoto H; Niwakawa M; Uemura H; Usami M; Terai A; Kanayama HO; Sumiyoshi Y; Eto M; Akaza H
Jpn J Clin Oncol; 2011 Jan; 41(1):17-24. PubMed ID: 20965941
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Urbanowitz G; Berg WJ; Kay A; Lebwohl D; Ravaud A;
Lancet; 2008 Aug; 372(9637):449-56. PubMed ID: 18653228
[TBL] [Abstract][Full Text] [Related]
3. Adverse event profile and dose modification of everolimus for advanced renal cell carcinoma in real-world Japanese clinical practice.
Nozawa M; Nonomura N; Ueda T; Nishimura K; Kanayama HO; Miki T; Nakatani T; Tomita Y; Azuma H; Yoshioka T; Tsujihata M; Uemura H
Jpn J Clin Oncol; 2013 Nov; 43(11):1132-8. PubMed ID: 23999768
[TBL] [Abstract][Full Text] [Related]
4. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
Calvo E; Escudier B; Motzer RJ; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Ravaud A; Kim D; Panneerselvam A; Anak O; Figlin RA
Eur J Cancer; 2012 Feb; 48(3):333-9. PubMed ID: 22209391
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.
Porta C; Calvo E; Climent MA; Vaishampayan U; Osanto S; Ravaud A; Bracarda S; Hutson TE; Escudier B; Grünwald V; Kim D; Panneerselvam A; Anak O; Motzer RJ
Eur Urol; 2012 Apr; 61(4):826-33. PubMed ID: 22297244
[TBL] [Abstract][Full Text] [Related]
6. Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis.
Bracarda S; Hutson TE; Porta C; Figlin RA; Calvo E; Grünwald V; Ravaud A; Motzer R; Kim D; Anak O; Panneerselvam A; Escudier B
Br J Cancer; 2012 Apr; 106(9):1475-80. PubMed ID: 22441644
[TBL] [Abstract][Full Text] [Related]
7. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Kay A; Ravaud A;
Cancer; 2010 Sep; 116(18):4256-65. PubMed ID: 20549832
[TBL] [Abstract][Full Text] [Related]
8. [Experience with everolimus therapy for patients with metastatic renal cancer in Hungary].
Maráz A; Bodoky G; Dank M; Géczi L; Kahán Z; Mangel L; Révész J; Szűcs M
Magy Onkol; 2014 Mar; 58(1):4-9. PubMed ID: 24712001
[TBL] [Abstract][Full Text] [Related]
9. Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial.
Ito T; Okusaka T; Ikeda M; Igarashi H; Morizane C; Nakachi K; Tajima T; Kasuga A; Fujita Y; Furuse J
Jpn J Clin Oncol; 2012 Oct; 42(10):903-11. PubMed ID: 22859827
[TBL] [Abstract][Full Text] [Related]
10. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.
Motzer RJ; Barrios CH; Kim TM; Falcon S; Cosgriff T; Harker WG; Srimuninnimit V; Pittman K; Sabbatini R; Rha SY; Flaig TW; Page R; Bavbek S; Beck JT; Patel P; Cheung FY; Yadav S; Schiff EM; Wang X; Niolat J; Sellami D; Anak O; Knox JJ
J Clin Oncol; 2014 Sep; 32(25):2765-72. PubMed ID: 25049330
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study.
Tomita Y; Fukasawa S; Shinohara N; Kitamura H; Oya M; Eto M; Tanabe K; Kimura G; Yonese J; Yao M; Motzer RJ; Uemura H; McHenry MB; Berghorn E; Ozono S
Jpn J Clin Oncol; 2017 Jul; 47(7):639-646. PubMed ID: 28419248
[TBL] [Abstract][Full Text] [Related]
13. Everolimus: in advanced renal cell carcinoma.
Garnock-Jones KP; Keating GM
Drugs; 2009 Oct; 69(15):2115-24. PubMed ID: 19791829
[TBL] [Abstract][Full Text] [Related]
14. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
Ferté C; Koscielny S; Albiges L; Rocher L; Soria JC; Iacovelli R; Loriot Y; Fizazi K; Escudier B
Eur Urol; 2014 Apr; 65(4):713-20. PubMed ID: 23993162
[TBL] [Abstract][Full Text] [Related]
15. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.
White DA; Camus P; Endo M; Escudier B; Calvo E; Akaza H; Uemura H; Kpamegan E; Kay A; Robson M; Ravaud A; Motzer RJ
Am J Respir Crit Care Med; 2010 Aug; 182(3):396-403. PubMed ID: 20194812
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
[TBL] [Abstract][Full Text] [Related]
17. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
Armstrong AJ; Halabi S; Eisen T; Broderick S; Stadler WM; Jones RJ; Garcia JA; Vaishampayan UN; Picus J; Hawkins RE; Hainsworth JD; Kollmannsberger CK; Logan TF; Puzanov I; Pickering LM; Ryan CW; Protheroe A; Lusk CM; Oberg S; George DJ
Lancet Oncol; 2016 Mar; 17(3):378-388. PubMed ID: 26794930
[TBL] [Abstract][Full Text] [Related]
18. Everolimus in metastatic renal cell carcinoma: preliminary experience from Chang Gung Memorial Hospital.
Huang WK; Liaw CC; Pang ST; Chuang CK; Chiang YJ; Wu CT; Chang YH; Wang HM; Lin YC; Hsieh JJ; Ou LY; Tsai SI; Yang CH; Yang CT; Chang JW
Chang Gung Med J; 2012; 35(5):402-7. PubMed ID: 23127345
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial.
Oyama M; Sugiyama T; Nozawa M; Fujimoto K; Kishida T; Kimura G; Tokuda N; Hinotsu S; Shimozuma K; Akaza H; Ozono S
Jpn J Clin Oncol; 2017 Jun; 47(6):551-559. PubMed ID: 28334974
[TBL] [Abstract][Full Text] [Related]
20. Patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma.
Mizuno R; Asano K; Mikami S; Nagata H; Kaneko G; Oya M
Jpn J Clin Oncol; 2012 May; 42(5):442-6. PubMed ID: 22438405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
